P1738

P1738 is a novel, non-thiazolidinedione (non-TZD) small molecule insulin sensitizer developed by Piramal Life Sciences for the treatment of type 2 diabetes and metabolic disorders. Unlike traditional thiazolidinediones such as rosiglitazone, P1738 does not activate peroxisome proliferator-activated receptor alpha (PPARα) or gamma (PPARγ) in transactivation assays. In preclinical mouse models of obesity and diabetes (including ob/ob, db/db, and diet-induced obese mice), oral administration of P1738 significantly reduced plasma glucose and triglyceride levels, improved glucose tolerance, and demonstrated a favorable safety profile without causing weight gain, hepatomegaly, or fluid retention.